BIOTRONIK Sets New Clinical Benchmark with Ultrathin Strut Orsiro Coronary Drug-Eluting Stent
Ticker Tech,
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
BÜLACH, Switzerland, Feb. 28, 2022 /PRNewswire/ -- BIOTRONIK is pleased to announce five-year data from the BIOFLOW-V trial…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
BÜLACH, Switzerland, Feb. 28, 2022 /PRNewswire/ -- BIOTRONIK is pleased to announce five-year data from the BIOFLOW-V trial…
BÜLACH, Switzerland, Feb. 28, 2022 /PRNewswire/ -- BIOTRONIK is pleased to announce five-year data from the BIOFLOW-V trial…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
BÜLACH, Switzerland, Feb. 28, 2022 /PRNewswire/ -- BIOTRONIK is pleased to announce five-year data from the BIOFLOW-V trial…
BÜLACH, Switzerland, Feb. 28, 2022 /PRNewswire/ -- BIOTRONIK is pleased to announce five-year data from the BIOFLOW-V trial…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
BÜLACH, Switzerland, Feb. 28, 2022 /PRNewswire/ -- BIOTRONIK is pleased to announce five-year data from the BIOFLOW-V trial…
BÜLACH, Switzerland, Feb. 28, 2022 /PRNewswire/ -- BIOTRONIK is pleased to announce five-year data from the BIOFLOW-V trial…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
BÜLACH, Switzerland, Feb. 28, 2022 /PRNewswire/ -- is pleased to announce five-year data from the BIOFLOW-V trial, which was…
BÜLACH, Switzerland, Feb. 28, 2022 /PRNewswire/ -- BIOTRONIK is pleased to announce five-year data from the BIOFLOW-V trial…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
BÜLACH, Switzerland, Feb. 28, 2022 /PRNewswire/ -- BIOTRONIK is pleased to announce five-year data from the BIOFLOW-V trial…
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical…
BÜLACH, Switzerland, Feb. 28, 2022 /PRNewswire/ -- is pleased to announce five-year data from the BIOFLOW-V trial, which was…
September 30, 2021—Biotronik announced it received FDA approval of its Orsiro Mission bioabsorbable polymer coronary drug-eluting…
LAKE OSWEGO, Ore., June 1, 2020 /PRNewswire/ -- today announced that it has received a group purchasing contract from Vizient…
Contract Offers Increased Savings to More than Half of Nation's Healthcare Organizations for BIOTRONIK's Coronary Products…
Contract Offers Increased Savings to More than Half of Nation's Healthcare Organizations for BIOTRONIK's Coronary Products…
Contract Offers Increased Savings to More than Half of Nation's Healthcare Organizations for BIOTRONIK's Coronary Products…
/PRNewswire/ -- BIOTRONIK today announced that it has received a group purchasing contract from Vizient, Inc., the largest…
, /PRNewswire/ -- BIOTRONIK today announced that it has received a group purchasing contract from Vizient, Inc., the largest…
Contract Offers Increased Savings to More than Half of Nation's Healthcare Organizations for BIOTRONIK's Coronary Products…
/PRNewswire/ -- BIOTRONIK today announced that it has received a group purchasing contract from Vizient, Inc., the largest…
/ / -- today announced that it has received a group purchasing contract from Vizient, Inc., the largest, member-driven…
BIOTRONIK Awarded Group Purchasing Contract for Coronary Products from Vizient Contract Offers Increased Savings to More than…
Contract Offers Increased Savings to More than Half of Nation's Healthcare Organizations for BIOTRONIK's Coronary Products…
Cardiovascular disease topped the list of pre-existing conditions that worsen COVID-19 mortality risk, at 10.5%.
Cardiovascular disease topped the list of pre-existing conditions that worsen COVID-19 mortality risk, at 10.5%.
SOURCE BIOTRONIK Data from BIOFLOW-V Trial Presented at CRT and Published in JACC: Cardiovascular Interventions Reinforces…
NATIONAL HARBOR, Md., Feb. 24, 2020 /PRNewswire/ -- BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which…
NATIONAL HARBOR, Md., Feb. 24, 2020 /PRNewswire/ -- today announced three-year data from the BIOFLOW-V trial, which was…
Data from BIOFLOW-V Trial Presented at CRT and Published in JACC: Cardiovascular Interventions Reinforces Orsiro's Ability to…
NATIONAL HARBOR, Md., /PRNewswire/ -- BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which was presented…
NATIONAL HARBOR, Md., Feb. 24, 2020 /PRNewswire/ -- BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which…
NATIONAL HARBOR, Md., Feb. 24, 2020 /PRNewswire/ -- BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which…
Data from BIOFLOW-V Trial Presented at CRT and Published in JACC: Cardiovascular Interventions Reinforces Orsiro's Ability to…
BIOTRONIK's Ultrathin Strut Orsiro Coronary Drug-Eluting Stent Continues to Deliver Excellent Results After Three Years Data…
NATIONAL HARBOR, Md., Feb. 24, 2020 /PRNewswire/ -- BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which…
Data from BIOFLOW-V Trial Presented at CRT and Published in JACC: Cardiovascular Interventions Reinforces Orsiro's Ability to…
NATIONAL HARBOR, Md., Feb. 24, 2020 / / -- BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which was…